Form 4: BioXcel Therapeutics CSO Increases Stake Through RSU Vesting

BioXcel Therapeutics, Inc.'s Chief Scientific Officer, Frank Yocca, Ph.D., has increased his direct beneficial ownership of common stock through the vesting and conversion of Restricted Stock Units (RSUs).

Summary

• Frank Yocca, Chief Scientific Officer of BioXcel Therapeutics, Inc. (BTAI), reported changes in his beneficial ownership of company securities.
• On June 14, 2025, Mr. Yocca acquired 33 shares of BioXcel Therapeutics Common Stock.
• On June 15, 2025, Mr. Yocca acquired an additional 35 shares of BioXcel Therapeutics Common Stock.
• These acquisitions resulted from the vesting and conversion of Restricted Stock Units (RSUs) into common stock.
• Following these transactions, Mr. Yocca directly beneficially owns 1,906 shares of Common Stock after the June 14 transaction and 1,941 shares after the June 15 transaction.
• The RSUs represent a contingent right to receive one share of the Issuer's Common Stock upon vesting.
• A grant of 521 RSUs was made on March 14, 2022, vesting 25% on the first anniversary and 6.25% quarterly thereafter, contingent on continuous employment.
• A separate grant of 562 RSUs was made on March 15, 2023, with the same vesting schedule of 25% on the first anniversary and 6.25% quarterly thereafter, also contingent on continuous employment.
• The filing indicates that 33 RSUs from the March 14, 2022 grant and 35 RSUs from the March 15, 2023 grant vested and converted into common stock.

Sentiment

Score: 6

Explanation: The sentiment is neutral to slightly positive. While a routine transaction, the increase in direct beneficial ownership by a key executive through RSU vesting is a standard part of compensation and indicates continued alignment with shareholder interests. There are no negative implications from this specific filing.

Positives

• The Chief Scientific Officer's direct beneficial ownership of company common stock increased, which can be viewed as a positive sign of alignment with shareholder interests.
• The transactions are a result of pre-scheduled RSU vesting, indicating a stable and expected compensation structure for key management.

Future Outlook

The document does not provide forward-looking statements or guidance regarding the company's financial performance or strategic direction, focusing solely on insider stock ownership changes.

Industry Context

This Form 4 filing is a routine disclosure of insider stock transactions, common across all publicly traded companies. It reflects a standard component of executive compensation plans, where Restricted Stock Units (RSUs) vest over time, converting into common stock. Such filings do not typically provide insights into broader industry trends or competitive positioning, but rather confirm the ongoing equity participation of key personnel.

Stakeholder Impact

• Shareholders: The increase in direct beneficial ownership by a key executive may be viewed positively as it aligns management's interests with those of shareholders.
• Employees: The vesting of RSUs is a standard component of executive compensation, reflecting the company's commitment to retaining and incentivizing key personnel.

Next Steps

• Continued vesting of remaining Restricted Stock Units (RSUs) held by Frank Yocca according to their respective schedules, subject to continuous employment.

Key Dates

Keywords

BioXcel Therapeutics, BTAI, SEC Form 4, Insider Trading, Stock Ownership, Restricted Stock Units, RSU Vesting, Frank Yocca, Chief Scientific Officer